Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Broncus Holding Corporation (BRNHF)
Hangzhou, CN
Broncus Holding Corporation is a medical technology enterprise dedicated to advancing interventional pulmonology through the development of specialized products. Its operational reach extends across key markets including Mainland China, the European Union, the United States, and other international regions. The company's product portfolio is broadly categorized into navigation and treatment solutions. Navigation offerings include: LungPoint Virtual Bronchoscopic Navigation: A sophisticated, computer-assisted software system that utilizes imaging for virtual bronchoscopic guidance. LungPoint Plus: This system provides real-time navigational assistance within the airways, crucial for lung biopsies and various other pulmonological procedures. LungPro: A virtual bronchoscopic navigation tool that facilitates three-dimensional, real-time guided transbronchial needle aspiration and features proprietary parenchymal navigation capabilities. Its comprehensive suite of treatment products comprises: InterVapor: A targeted bronchoscopic thermal vapor ablation method designed to treat diseased, hyper-inflated lung segments. RF Generator + RF Ablation Catheter: A radiofrequency ablation system specifically engineered for use with a disposable lung radiofrequency ablation catheter, targeting lung cancer. H-Marker: A specialized marker for pulmonary surgical applications. Furthermore, Broncus provides essential procedural accessories and tools such as: BioStarNeedle: A single-use, ultrasound-guided aspiration needle for efficiently collecting tissue samples. FleXNeedle: A versatile biopsy needle adaptable for multiple purposes. Archimedes Sheath: A sterile, single-use flexible tube that establishes a working channel during bronchoscopic interventions. Archimedes Dilation Balloon: A sterile, single-use flexible tube equipped with a balloon at its tip, inserted via a bronchoscope or sheath to dilate targeted lung tissue within the bronchial tree. Steerable Sheath: Featuring a steerable adjustment handle and a working channel for enhanced maneuverability. Broncus Holding Corporation was established in 2012 and maintains its corporate headquarters in Hangzhou, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | -73.94% | -73.94% | -73.94% | -73.94% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Medical - Devices: +11.2%-20.7% Q2'25: -68.4% (vs Q2'23)
-
EPS growth Medical - Devices: +28.5%+46.1% ★ Q2'25: +46.4% (vs Q2'23)
-
FCF margin FCF growth · Medical - Devices: +30.9%-140.6% Q2'25: -288.6% (vs Q2'23)
-
EBIT margin Medical - Devices: +6.2%-187.1% Q2'25: -744.6% (vs Q2'23)
-
ROIC Medical - Devices: +3.3%-49.6% Q2'25: -164.5% (vs Q2'23)
-
Share dilution Medical - Devices: 0.0%+0.0% ★ Q2'25: -1.4% (vs Q2'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-0.03× Q2'25: 0.00× (vs Q2'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. |
Dec 2027 1 Rev. Ana. |
Dec 2028 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
10.86M
est: 9.03M (+20.2%)
|
9.44M
est: 13.34M (-29.3%)
|
10.26M
est: 15.19M (-32.5%)
|
8.13M
est: 13.03M (-37.6%)
|
11.81M
est.
|
16.96M
16.96M – 16.96M
+43.6% YoY
|
21.87M
21.87M – 21.87M
+29.0% YoY
|
86.00M
86.00M – 86.00M
+293.2% YoY
|
| EBITDA |
-232.55M
est: -9.03M (-2,474.8%)
|
-25.15M
est: -13.34M (-88.5%)
|
-25.05M
est: -15.19M (-64.9%)
|
-12.01M
est: -13.03M (+7.9%)
|
-11.81M
est.
|
-16.96M
-16.96M – -16.96M
-43.6% YoY
|
-21.87M
-21.87M – -21.87M
-29.0% YoY
|
-86.00M
-86.00M – -86.00M
-293.2% YoY
|
| EBIT |
-236.01M
est: -9.03M (-2,513.1%)
|
-27.94M
est: -13.34M (-109.5%)
|
-27.93M
est: -15.19M (-83.8%)
|
-15.22M
est: -13.03M (-16.8%)
|
-11.81M
est.
|
-16.96M
-16.96M – -16.96M
-43.6% YoY
|
-21.87M
-21.87M – -21.87M
-29.0% YoY
|
-86.00M
-86.00M – -86.00M
-293.2% YoY
|
| Net Income |
-235.01M
est: -52.43M (-348.2%)
|
-28.10M
est: -43.97M (+36.1%)
|
-28.09M
est: -24.43M (-15.0%)
|
-15.30M
est: -4.89M (-213.2%)
|
—
est.
|
—
— – —
|
—
— – —
|
—
— – —
|
| SGA |
31.25M
est: 23.43M (+33.4%)
|
20.42M
est: 34.63M (-41.0%)
|
20.42M
est: 39.44M (-48.2%)
|
15.76M
est: 34.63M (-54.5%)
|
31.39M
est.
|
45.08M
45.08M – 45.08M
+43.6% YoY
|
58.12M
58.12M – 58.12M
+29.0% YoY
|
228.56M
228.56M – 228.56M
+293.2% YoY
|
| EPS |
-0.45
est: -0.11 (-319.3%)
|
-0.06
est: -0.09 (+36.0%)
|
-0.06
est: -0.05 (-15.0%)
|
-0.03
est: -0.01 (-210.0%)
|
—
est.
|
—
— – —
|
—
— – —
|
—
— – —
|
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hong Xu | Chairman of the Board & Chief Executive Officer | 206.0K | male |
| Elaine Lu | Director of Finance & Administration | — | female |
| Feng Yao | Sr. Accountant | — | — |
| Ka Yan Suen | Company Secretary | — | female |
| Thomas Keast | Vice President, Operation Director & Scientist in resident | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BRNHF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
